A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old
NCT07477132
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
99
Enrollment
OTHER
Sponsor class
Conditions
Curarization, Postoperative Residual
Interventions
DRUG:
Sugammadex
Sponsor
University Hospital, Caen